

Canadian Association of Provincial Cancer Agencies

Strategic Plan 2020 to 2023

OUR VISION

Pan-Canadian cancer control systems that are collaborative, person-centred and high-performing by international standards.

OUR MISSION

To improve cancer control systems across Canada by working together to enhance quality, support innovation and strengthen sustainability.




Enhancing Quality

Improving quality of cancer control is a goal shared by every provincial cancer program. CAPCA is committed to monitoring and improving patient safety, expanding access to diagnostic screening, and improving palliative care. Identifying opportunities to create, implement and endorse standards of care that will lead to more harmonized care for cancer patients is another important consideration.

Key priorities:

- 1.1 Improving patient safety through better and more integrated data.
- 1.2 Expanding lung cancer screening.
- 1.3 Improving integration of palliative care.
- 1.4 Prioritizing and implementing pan-Canadian standards.

Pillar 1



Supporting Innovation

Supporting innovation in cancer care is imperative for patients and care teams to access new tools, techniques and therapies. CAPCA is committed to building on expertise gained during development of the clinical access framework for the introduction of CAR T-cell therapy in Canada, and to capture and integrate insights gathered from initiatives such as the multi-jurisdictional procurement for radiation treatment linear accelerators.

Key priorities:

- 2.1 Coordinating access to CAR T-Cell therapy.
- 2.2 Leveraging learnings from previous access to care initiatives.

Pillar 2



Strengthening Sustainability

Given current demographic trends, treatment costs and budgetary constraints, CAPCA actively supports its members in their efforts to ensure sustainability of cancer systems across Canada. CAPCA is committed to strengthening system sustainability.

Key priorities:

- 3.1 Integrating drug implementation issues into CADTH.
- 3.2 Forging a collective response to system shortages.
- 3.3 Optimizing the use of oncology biosimilars.
- 3.4 Incorporating lessons from real-world evidence into formulary management.
- 3.5 Developing and implementing new models of care.

Pillar 3

